Patient-derived organoids (PDOs) and PDO-derived xenografts (PDOXs): New opportunities in establishing faithful pre-clinical cancer models

IF 7.6 Q1 ONCOLOGY

Journal of the National Cancer Center Pub Date : 2022-12-01 DOI:10.1016/j.jncc.2022.10.001

Ergang Wang , Kun Xiang , Yun Zhang , Xiao-Fan Wang

{"title":"Patient-derived organoids (PDOs) and PDO-derived xenografts (PDOXs): New opportunities in establishing faithful pre-clinical cancer models","authors":"Ergang Wang , Kun Xiang , Yun Zhang , Xiao-Fan Wang","doi":"10.1016/j.jncc.2022.10.001","DOIUrl":null,"url":null,"abstract":"<div><p>One of the major bottlenecks in advancing basic cancer research and developing novel cancer therapies is the lack of <em>in vitro</em> pre-clinical models that faithfully recapitulate tumor properties in the patients. Monolayer cultures of cancer cell lines usually lose the heterogeneity of the parental tumors, while patient-derived xenograft (PDX) suffers from its time- and resource-intensive nature. The emergence of organoid culture system and its application in cancer research provides a unique opportunity to develop novel <em>in vitro</em> cancer pre-clinical models. Here we review the recent advances in utilizing organoids culture system and other related three-dimensional culture systems in studying cancer biology, performing drug screening, and developing cancer therapies. In particular, we discuss the advantages of applying xenograft initiated from patient-derived organoids (PDOs) as a faithful cancer pre-clinical model in basic cancer research and precision medicine.</p></div>","PeriodicalId":73987,"journal":{"name":"Journal of the National Cancer Center","volume":"2 4","pages":"Pages 263-276"},"PeriodicalIF":7.6000,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667005422000679/pdfft?md5=bb006fd428deb8fd511d5a4d51d3bd15&pid=1-s2.0-S2667005422000679-main.pdf","citationCount":"7","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the National Cancer Center","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2667005422000679","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 7

Abstract

One of the major bottlenecks in advancing basic cancer research and developing novel cancer therapies is the lack of in vitro pre-clinical models that faithfully recapitulate tumor properties in the patients. Monolayer cultures of cancer cell lines usually lose the heterogeneity of the parental tumors, while patient-derived xenograft (PDX) suffers from its time- and resource-intensive nature. The emergence of organoid culture system and its application in cancer research provides a unique opportunity to develop novel in vitro cancer pre-clinical models. Here we review the recent advances in utilizing organoids culture system and other related three-dimensional culture systems in studying cancer biology, performing drug screening, and developing cancer therapies. In particular, we discuss the advantages of applying xenograft initiated from patient-derived organoids (PDOs) as a faithful cancer pre-clinical model in basic cancer research and precision medicine.

查看原文本刊更多论文

患者来源的类器官（PDO）和PDO来源的异种移植物（PDOX）：建立忠实的临床前癌症模型的新机会

推进基础癌症研究和开发新型癌症疗法的主要瓶颈之一是缺乏能够忠实地概括患者肿瘤特性的体外临床前模型。单层培养的癌细胞通常失去了亲代肿瘤的异质性，而患者来源的异种移植物(PDX)则受到时间和资源密集型的影响。类器官培养系统的出现及其在癌症研究中的应用为开发新型体外癌症临床前模型提供了独特的机会。本文综述了近年来利用类器官培养系统和其他相关三维培养系统在肿瘤生物学研究、药物筛选和癌症治疗方面的研究进展。我们特别讨论了将患者源性类器官(PDOs)作为基础癌症研究和精准医学中可靠的癌症临床前模型的异种移植的优势。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊